EUR-Lex & EU Commission AI-Powered Semantic Search Engine
Modern Legal
  • Query in any language with multilingual search
  • Access EUR-Lex and EU Commission case law
  • See relevant paragraphs highlighted instantly
Start free trial

Similar Documents

Explore similar documents to your case.

We Found Similar Cases for You

Sign up for free to view them and see the most relevant paragraphs highlighted.

Case C-786/18: Request for a preliminary ruling from the Bundesgerichtshof (Germany) lodged on 14 December 2018 — ratiopharm GmbH v Novartis Consumer Health GmbH

ECLI:EU:UNKNOWN:62018CN0786

62018CN0786

December 14, 2018
With Google you find a lot.
With us you find everything. Try it now!

I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!

Valentina R., lawyer

25.3.2019

EN

Official Journal of the European Union

C 112/23

(Case C-786/18)

(2019/C 112/28)

Language of the case: German

Referring court

Parties to the main proceedings

Appellant on a point of law: ratiopharm GmbH

Respondent in the appeal on a point of law: Novartis Consumer Health GmbH

Questions referred

1.Is Article 96(1) of Directive 2001/83/EC (1) to be interpreted as meaning that pharmaceutical companies may also distribute free finished medicinal products to pharmacists, if their packaging is labelled ‘for demonstration purposes’, the medicinal products are used by the pharmacist to test the product, there is no risk of further distribution (of the unopened product) to end users and the further conditions for distribution set out in Article 96(1)(a) to (d) and (f) to (g) of that directive are met?

2.If the answer to Question 1 is in the affirmative: Does Article 96(2) of Directive 2001/83/EC permit a national provision such as Paragraph 47(3) of the Arzneimittelgesetz (Law on medicinal products; ‘the AMG’), if that provision is interpreted as meaning that pharmaceutical companies may not distribute free finished medicinal products to pharmacists, if their packaging is labelled ‘for demonstration purposes’, the medicinal products are used by the pharmacist to test the product, there is no risk of further distribution (of the unopened product) to end users and the further conditions for distribution set out in Article 96(1)(a) to (d) and (f) to (g) of that directive and in Paragraph 47(4) of the AMG are met?

Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ 2001 L 311, p. 67), in the version last amended by Regulation (EU) No 2017/745 (OJ 2017 L 117, p. 1).

* * *

EurLex Case Law

AI-Powered Case Law Search

Query in any language with multilingual search
Access EUR-Lex and EU Commission case law
See relevant paragraphs highlighted instantly

Get Instant Answers to Your Legal Questions

Cancel your subscription anytime, no questions asked.Start 14-Day Free Trial

At Modern Legal, we’re building the world’s best search engine for legal professionals. Access EU and global case law with AI-powered precision, saving you time and delivering relevant insights instantly.

Contact Us

Tivolska cesta 48, 1000 Ljubljana, Slovenia